At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed May 12, 2026 at 13:33 ET
Skye Bioscience reported Q1 2026 EPS of -$0.32, missing consensus of -$0.29 by 10.3%, with a net loss of $12.5M vs $11.1M a year ago. The company highlighted clinical progress in its CBeyond expansion study for nimacimab but faces a cash runway only through Q4 2026, excluding Phase 2b costs, creating significant funding uncertainty.
- Q1 2026 EPS -$0.32 vs consensus -$0.29 (10.3% miss)
- Net loss widened to $12.5M from $11.1M YoY
- Cash, equivalents and short-term investments: $17.1M as of March 31, 2026
- Cash runway only through Q4 2026, excluding Phase 2b costs
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access